Clinical trial
Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in…
NCT00156273 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00156273 |
|---|---|
| Title | Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer |
| Official title | A Pilot Study to Determine the Feasibility of Quantifying Apoptosis and Bcl-2 Expression in Circulating Tumor Cells (CTCs) in Women Undergoing Treatment for Metastatic Breast Cancer |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Status | Completed |
| Study type | Observational |
| Conditions | Metastatic Breast Cancer |
| Enrollment | 69 |
| Start date | Apr 1, 2005 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Sep 12, 2005 |
| Last update posted | Jul 5, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: